Skip to main content
. 2022 Jun 28;14:2107–2117. doi: 10.2147/CMAR.S330398

Figure 2.

Figure 2

Blastic plasmacytoid dendritic cell neoplasm: novel therapeutic agents and their targets. Blue text highlights the commercially available medications for either BPDCN or other hematologic malignancies.